Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bide Pharmatech CoSHSE:688073 +9.28%86 OCF Margin % is 12.20% as of Mar. 2026, which is 1040% above its 10-year median of 1.07. GuruFocus rates SHSE:688073 with a GF Score™ of 86/100 and a GF Value™ of ¥67.40 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 964 Drug Manufacturers companies, Bide Pharmatech Co ranks worse than 63.49% on this metric.
The historical rank and industry rank for Bide Pharmatech Co's OCF Margin % or its related term are showing as below:
SHSE:688073'
s OCF Margin % Range Over the Past 10 Years
Min: -10.7 Med: 1.07 Max: 14.37
Current: 4.49
During the past 8 years, the highest OCF Margin % of Bide Pharmatech Co was 14.37%. The lowest was -10.70%. And the median was 1.07%.
SHSE:688073's OCF Margin % is ranked worse than 63.49% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.025
vs SHSE:688073: 4.49
The historical data trend for Bide Pharmatech Co's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bide Pharmatech Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bide Pharmatech Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bide Pharmatech Co (SHSE:688073) has a OCF Margin % of 12.20% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bide Pharmatech Co and its competitors. This is 1040% above median its historical median of 1.07. According to the industry distribution chart, Bide Pharmatech Co ranks #612 out of 964 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is Bide Pharmatech Co's OCF Margin % too high?
Bide Pharmatech Co's current OCF Margin % of 12.20% is 1040% above median its 10-year median of 1.07. The Drug Manufacturers industry median OCF Margin % is 10.03. Bide Pharmatech Co's value of 12.20% is 21.7% above this industry median. Based on the distribution chart, Bide Pharmatech Co ranks #612 out of 964 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bide Pharmatech Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bide Pharmatech Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bide Pharmatech Co ranks #612 out of 964 companies for OCF Margin %. This places Bide Pharmatech Co in the lower half of its industry. The industry median OCF Margin % is 10.03. Bide Pharmatech Co's value of 12.20% is 21.7% above this benchmark. While the company's 10-year median is 1.07 vs. the industry median of 10.03, Bide Pharmatech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.03, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bide Pharmatech Co's current OCF Margin % of 12.20% is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bide Pharmatech Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bide Pharmatech Co's current OCF Margin % is 12.20%, which is 1040% above median its own 10-year median of 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bide Pharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, Bide Pharmatech Co (SHSE:688073) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥67.40, compared to a current price of ¥50.65 — trading 24.9% below its estimated fair value. The current OCF Margin % is 12.20%, which is 1040% above median its 10-year median of 1.07 and 21.7% above the Drug Manufacturers industry median of 10.03. Bide Pharmatech Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bide Pharmatech Co (SHSE:688073), the current OCF Margin % is 12.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bide Pharmatech Co (SHSE:688073) Overvalued in 2026?
Based on GuruFocus' analysis, Bide Pharmatech Co stock appears to be undervalued.
The current stock price of ¥50.65 is trading 24.9% below its estimated GF Value™ of ¥67.40.
GuruFocus considers Bide Pharmatech Co to be Modestly Undervalued.
Key valuation signals for SHSE:688073:
OCF Margin %: 12.20% (1040% above median its 10-year median of 1.07)
GF Value™: ¥67.40 vs. price of ¥50.65 (24.9% below fair value)
Industry Position: 21.7% above the Drug Manufacturers median (#612 of 964)
No single metric tells the full story. See the SHSE:688073 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688073 has been successfully added to your 
